The genetic understanding of cancer has led to enhanced individual risk assessment, improved screening guidelines, and improved outcomes based on cancer prevention, early detection, and, in some cases, targeted therapy. Huntsman Cancer Institute (HCI) is positioned to make exceptional contributions in this individualized oncology arena. HCI has a unique research resource to support genetic and population studies, the Utah Population Database (UPDB), a compelling history of genetic discovery in oncology, and a strategic plan to accelerate translational advances from this platform. We have forged an alliance with Intermountain Healthcare, a nationally acclaimed Utah health network, linking data for more than 80-85 percent of the cancer patients in our State to the UPDB, enabling the entire population of Utah to comprise a cancer research laboratory for genetic, population, and outcomes research. Utah is home to seven Native American tribes or nations as well as extensive rural and frontier populations that have poor cancer outcomes.
We aim to serve as a national research resource for addressing the needs of these underserved populations to improve cancer prevention and care. HCI research is organized into five Programs that provide an environment of cancer focus, transdisciplinary exchange, and collaboration: Nuclear Control of Cell Growth and Differentiation;Cell Response and Regulation;Imaging, Diagnostics, and Therapeutics;Gastrointestinal Cancers;and Cancer Control and Population Sciences. These Programs integrate the activities of 133 members who have $45 million in extramural grant support, with more than $17 million in NCI direct costs. Cancer-focused research during the current award period is documented in 1,374 unique publications, of which 26 percent are collaborative with one or more Cancer Center members. Thirteen Cancer Center Shared Resources support our scientists, providing access to specialized instrumentation, assays, services, research materials, and expert consultation and collaboration. We request funds to support Years 21-25 of our Cancer Center Support Grant (CCSG). A new Executive Director, Mary Beckerle, Ph.D., was appointed in August 2006. Under her leadership, HCI has developed a plan to guide the next five years, including expansion of HCI's cancer specialty hospital, expansion of HCI's genetic platform for pre-clinical studies, development of a Center for Investigational Therapeutics (including a Phase I program), and expansion of population science (including epidemiological and behavioral research) to impact care of cancer survivors and reduce health disparities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-23S1
Application #
8533380
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-05-09
Project End
2015-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$24,833
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Polanco, Edward R; Western, Nicholas; Zangle, Thomas A (2018) Fabrication of Refractive-index-matched Devices for Biomedical Microfluidics. J Vis Exp :
Sorenson, Reed S; Deshotel, Malia J; Johnson, Katrina et al. (2018) Arabidopsis mRNA decay landscape arises from specialized RNA decay substrates, decapping-mediated feedback, and redundancy. Proc Natl Acad Sci U S A 115:E1485-E1494
Nevala-Plagemann, Christopher; Francis, Samual; Cavalieri, Courtney et al. (2018) Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 3:e000386
Camolotto, Soledad A; Pattabiraman, Shrivatsav; Mosbruger, Timothy L et al. (2018) FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife 7:
Wu, Yelena P; Nagelhout, Elizabeth; Aspinwall, Lisa G et al. (2018) A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns 101:452-459
Li, Lian; Yang, Jiyuan; Wang, Jiawei et al. (2018) Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. ACS Nano 12:3658-3670
Ferris, Elliott; Abegglen, Lisa M; Schiffman, Joshua D et al. (2018) Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance. Cell Rep 22:2742-2755
Tiburcio, Patricia D B; Xiao, Bing; Chai, Yi et al. (2018) IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment. Oncotarget 9:35100-35113
Ou, Judy Y; Fowler, Brynn; Ding, Qian et al. (2018) A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer 18:115
Liang, Wenjie; Yang, Pengfei; Huang, Rui et al. (2018) A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Clin Cancer Res :

Showing the most recent 10 out of 1193 publications